OTCPicks.com

FORTRESS INTERNATIONAL GROUP INCORPORATED (NASDAQ: FIGI)
"Up 82.81% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/FIGI.php

Fortress International Group Inc. (FIGI) and its subsidiaries Total Site Solutions, Rubicon, Vortech, and Innovative Power, plan, design, build and maintain specialized facilities such as data centers, trading floors, call centers, laboratories, medical facilities, network operation centers, communication facilities, and secure facilities. For nearly 30 years, the FIGI team has pioneered building robust and scalable infrastructure into mission-critical facilities. The firm offers unsurpassed expertise in the infrastructure systems (electrical, mechanical, telecommunications, security, fire protection and building automation) that are the critical facility's lifeblood. FIGI's comprehensive portfolio of services and multi-disciplinary expertise provide customers a highly respected single source for critical services that bridge the gap between IT and facilities.

FIGI News:

August 27 - Fortress International Group Executives Convert $3.5mm of Sellers' Notes to Stock at Original Conversion Price of $7.50 per Share

* Executive and Board Compensation is Reduced by $750,000 Annually
* Remaining $4mm Seller's Note Restructured to Delay Interest and Principal Payments Until 2010

Fortress International Group (Nasdaq: FIGI), a company providing comprehensive services for the planning, design and development of mission-critical facilities and information infrastructure, announced that its two most senior executives, Tom Rosato, CEO and Jerry Gallagher, President, converted $3,500,000 of seller's notes to equity at the original $7.50 share price. This action has eliminated the balance of the Rosato note in full on the balance sheet. Gallagher agreed to defer interest and principal payments on the balance of his note until the first quarter of 2010. These actions will reduce cash payments on the notes of approximately $225k in 2008 and $2.3mm in 2009.

In addition to this restructuring of the balance sheet Messrs. Rosato, Gallagher and members of the board of directors took reductions in their annual compensation totaling $750,000, none of which was replaced in stock compensation. It had previously been disclosed that members of the board of directors would receive stock compensation in lieu of reduced cash compensation.

Commenting on the announcement, Tom Rosato said, "Our decision to convert a sizeable portion of our note will not only reduce debt, improve cash flow and enhance the balance sheet of the company, but it should also serve as a demonstration of the complete confidence we have in our business model and ability to move from a period of slow backlog turnover to profitable quarters. Along with significant pay cuts taken by Gallagher and myself, the pay reduction of board members and additional overhead reduction measures, these actions will assist the company in recovering its EBITDA losses experienced in the past six quarters. My sole interest is to bring our company to cash flow positive and in the process increase shareholder value to our investors."

Jerry Gallagher, President, added: "We are securing business with outstanding customers who trust us with the engineering and development of their critical assets and resources. Our Technology Consulting business is very strong and for those who understand our business model, TC is the precursor to projects with large positive cash flow. Because of this, I am joining with Tom, to make similar concessions regarding salary as well as converting $1 million of my seller note to stock. I am also restructuring the balance of my seller note to delay principal payments and interest payments until March 2010."

GOOD LIFE CHINA CORPORATION (OTC: GLCC)
"Up 87.50% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/GLCC.php

Good Life China Corporation operates a chain of franchised convenience stores in Hebei Province, the People’s Republic of China. The company employs retail concepts, such as e-commerce enabled POS/back office systems. It operates approximately 1,730 stores. The company also has an agreement with Petro China Beijing to provide distribution services and information management system services for the convenience stores in the gas stations belonging to Petro China Beijing Marketing Company. In addition, the company offers online sub prime financial services, such as money lending, forex trading, and advanced electronic funds management. Good Life China Corporation was incorporated in 1998 and is based in Toronto, Canada.

GLCC News:

August 26 - Good Life China Corporation Announces New Store Openings

Good Life China Corporation (OTC: GLCC) (www.goodlifechina.com) announced additional new store openings. A total of 19 stores have been opened within the last 10 days, including stores in Cangzhou, Shijiazhuang and a number of smaller villages. In addition, 3 new suppliers were added to the Good Life Corporation network.

While a number of major announcements regarding strategic alliances and acquisitions have been made in recent days, it is important to note that Good Life continues to generate organic growth with an ongoing stream of new store openings at a very aggressive pace.

When considered in light with the ongoing negotiations to acquire "The People Home" Chain (TPH), it is anticipated that Good Life may soon surpass 3,000 stores.

In other Company news, the Company has signed a strategic partnership agreement with Hebei Provincial General Supply and Marketing Cooperative Corp., after a successful meeting to discuss coordinating efforts in line with China's high priority "10,000 rural village and 1000 Townships" economic development policy to open modern retail stores in rural areas across China. This agreement can help accelerate Good Life's ongoing objective to achieve a store count of 4,000 convenience stores as quickly as possible.

AMERICAN BIO MEDICA CORPORATION (NASDAQ: ABMC)
"Up 38.89% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/ABMC.php

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay diagnostic test kits, including some of the world’s most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC’s Rapid Drug Screen®, Rapid ONE®, Rapid TEC®, RDS® InCup®, Rapid TOX and Rapid TOX Cup® products test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ tests for the presence or absence of drugs of abuse in oral fluids. ABMC’s Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

ABMC News:

August 27 - FDA Grants CLIA Waiver to ABMC for Its Drug Test

American Bio Medica Corporation (Nasdaq: ABMC) announced that the US Food and Drug Administration (FDA) has granted CLIA waived status to the Company's Rapid TOX® point of collection drug test product line. The waiver applies to all 14 drugs that the Company currently tests for in addition to two different cut-off levels for its Opiate and Cocaine tests. CLIA waived tests are recognized by FDA to be so simple to use and so accurate that there is little risk of error. CLIA waived tests are the most widely used tests in the clinical market (hospitals and physicians), and are in-demand for occupational health and criminal justice applications.

ABMC Chief Executive Office Stan Cipkowski stated, “We have been waiting some time for this decision from the FDA and we are pleased to finally receive our CLIA waiver. The granting of the CLIA waiver is expected to greatly impact our relationship with our laboratory alliance as up until this point, the lab alliance has been obtaining CLIA waived devices from another supplier. Now that our Rapid TOX device is CLIA waived, they will be obtaining all of their urine based point of collection devices from ABMC.”

Cipkowski added, “CLIA waiver also allows us to complete our negotiations with several distributors who service the physician and hospital market. We are anxious to be able to penetrate new markets with our products and this waiver opens the first door for us. I expect to see an immediate impact on sales beginning in the fourth quarter of this year and ramping up throughout 2009.” Cipkowski continued, “In spite of the problems and expenses related to this in 2007, our Chief Science Officer Martin Gould and Director of Quality Assurance and Regulatory Affairs Richard Reilly have completed this first waiver well under budget in 2008. We expect future waiver applications to be more cost effective and expedient due to their efforts.”

THE ANVIRON HOLDING COMPANY (OTC: ANVH)
"Up 33.33% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/ANVH.php

Anviron is a company dedicated to bringing to market "Clean Solutions to Complex Problems" by offering a wide range of biodegradable, environmentally friendly products and technologies that will substitute for many of the hazardous chemicals commonly used all over the world. For information about Anviron and its product offerings visit www.anviron.com.

ANVH News:

August 27 - Anviron Announces Long-Term Debt Reduction and Share Structure Changes

The Anviron Holding Company (OTC: ANVH) (“Anviron”), a manufacturer and marketer of "Clean & Green" products and technology, announced that it has filed an Amendment to the Articles of Incorporation reducing the conversion rights of its preferred stock. In addition, the company announced the reduction of its remaining long-term debt by $239,000 USD.

"As our cash reserves begin to grow after the trying and difficult growth phase we have experienced, the company has been able to reduce our long term debt by more than $239,000 in the month of August. This reduction is a pivotal step in controlling our shareholder base, as this reduction also eliminates the last remaining convertible note posted on the books of the company,” stated Marcie Corbin acting CFO of Anviron.

The company in an effort to position itself in the most favorable like to investors has taken the steps in cooperation with its largest shareholders to reduce the current conversion rights of its preferred stock. “We have filed today an amendment to the articles of incorporation that will reduce the current conversion rights of our preferred stock and place a three year vesting provision on the shares,” stated Polly Anderson – Investor Relations Manager for Anviron. “Upon completion of this task with the State of Delaware, we will have dramatically increased our diluted earning per share calculations for the company and reduced investors concerns over potential short term dilution into the market.”

The new provisions will require a three-year vesting of the preferred shares, prior to any conversion into common stock in the company. The voting rights of the shares have not been modified, and the “founders” will continue to have the right to convert common shares to preferred shares without notice.

ZILA INCORPORATED (NASDAQ: ZILA)
"Up 16.67% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/ZILA.php

Zila, Inc., is a fully integrated oral diagnostic company dedicated to the prevention, detection and treatment of oral cancer and periodontal disease. ViziLite® Plus with TBlue™, the company's flagship product for the early detection of oral abnormalities that could lead to cancer, is the first and only adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer. In addition, Zila designs, manufactures and markets a suite of proprietary products sold exclusively and directly to dental professionals for periodontal disease, including the Rotadent® Professional Powered Brush, the Pro-Select Platinum® ultrasonic scaler and a portfolio of oral pharmaceutical products for both in-office and home-care use.

ZILA News:

August 27 - Zila Adds Four Major European Markets for Its Proprietary Oral Cancer Screening Product, ViziLite Plus

Company Names Dentaid Marketing Partner for Spain, France, Germany and Portugal

Zila, Inc. (Nasdaq: ZILA) announced that it has selected Dentaid to be the exclusive distributor of ViziLite® Plus with TBlue™, Zila’s proprietary oral cancer screening product, in Spain, France, Germany and Portugal. Dentaid is the market leader among dental distributors in France and Spain, and has recently established a significant presence in the German market. Terms of the agreement were not disclosed.

ViziLite® Plus with TBlue™ is now available to 55% of the people in the Western and Eastern EU-member countries; Zila previously announced that it had selected distributors for the product in the United Kingdom, Ireland, Greece and Cyprus.

“The marketing of ViziLite Plus in Spain, France, Germany, and Portugal provides a solid core of countries in Europe with an important new oral cancer screening tool,” said David Bethune, chairman and chief executive officer of Zila. "We believe Dentaid’s direct selling force will communicate the unique attributes of ViziLite Plus to the dental healthcare community and build it into a leading brand in these markets.”

ViziLite® Plus with TBlue™, Zila's flagship product for the early detection of oral abnormalities that could lead to cancer, is the first and only adjunctive medical device cleared by the FDA for use in a population at increased risk for oral cancer.

“ViziLite Plus is a much needed oral cancer screening product for the practitioners that we call on,” said Enric Masdevall, president and chief executive officer of Dentaid Europe. “Given that 25% of oral cancers occur in people who do not smoke and have no other behavioral risk factors, it is imperative that every adult, particularly those at high risk for oral cancer, be screened at least once a year. ViziLite Plus is a proven technology and will be a valuable aid in screening for precancerous lesions and early stage cancers before they reach more severe stages.”

The combined population of Spain, France, Germany and Portugal exceeds 195 million.

ABOUT ORAL CANCER AND VIZILITE PLUS

Oral cancer is the sixth leading cause of cancer worldwide, and in the U.S., one person dies every hour from the disease. According to American Cancer Society data, nearly as many women will be diagnosed with oral cancer as with cervical cancer this year. The key to reducing the impact of this disease is early detection, yet prior to the introduction of ViziLite Plus the only screening tools available were the manual and visual exam, which helps explain why the mortality and morbidity associated with oral cancer have not markedly improved in the past 40 years. Worldwide clinical trials have demonstrated that the conventional visual/tactile examination may fail to identify up to 40% of cancers and precancers. In other studies the addition of ViziLite Plus to conventional examination has been shown in the literature to result in identification of 100% of pathological lesions.

ViziLite Plus, an oral screening technology that utilizes a chemiluminescent light source (ViziLite) and a patented vital tissue dye (TBlue), helps dentists and dental technicians identify and evaluate abnormalities in the mouth that could potentially harbor pathologic changes. The ViziLite Plus exam takes only minutes and is totally painless and non-invasive.

Oral Cancer Risk factors:

Age - all adults
Tobacco use - particularly if combined with heavy alcohol consumption
Heavy alcohol consumption
Excessive sun exposure to the lips
Sexually transmitted virus exposure (HPV)

A recent report in the New England Journal of Medicine suggests that exposure to the sexually transmitted human papillomavirus number 16 (HPV16), causes oropharyngeal cancer (a type of oral cancer), and may help explain the increasing incidence of the disease in younger people.

ABOUT DENTAID

Dentaid is a recognized leader with international prestige in the field of oral hygiene. Dentaid was created in 1980 with a clear mission to investigate, develop and commercialize products aimed at preventing, diagnosing and treating diseases produced by dental bacterial plaque, by either physical, chemical or biological means. The aim of Dentaid is to improve the oral health of the general population by creating products that not only offer the best solutions, but that are backed scientifically by dental professionals.

ADVANCED ID CORPORATION (OTCBB: AIDO)
"Up 30.00% on Wednesday"

Detailed Quote: http://www.otcpicks.com/quotes/AIDO.php

Advanced ID Corporation is a complete solutions provider in the RFID market with a focus on the tire management industry. The company is also a major factor in the tire inspection business through its UK-based Pneu-Logic subsidiary. The Company is active in the pet recovery business through its AVID Canada subsidiary in Calgary, Alberta, is reintroducing its livestock tagging product line in several countries and has developed a UHF RFID reader product line for all market applications.

AIDO News:

August 27 - Advanced ID Corp. Rated 'Speculative Buy,' Target Price $0.35 by Beacon Equity Research

Advanced ID Corp. (OTCBB: AIDO) has been rated Speculative Buy with a price target of $0.35 by Beacon Analyst, Victor Sula, Ph.D.

The full report is available at www.beaconequity.com/adpages/AIDO.

In the report, the analyst writes, “The Company is emerging as a leading integrated RFID solutions provider with product lines for animal recovery and asset management applications. Its readers are being tested by major companies in the tire management, document control, pharmaceutical, vehicle ID, food services and general retail industries … AIDO is also a major player in the RFID tire tag/patch segment, which is growing at double- to triple-digit rates.”

Other companies in the RFID sector include: Intermec Inc. (NYSE: IN), Zebra Technologies Inc. (Nasdaq: ZBRA), Aruba Networks Inc. (Nasdaq: ARUN) and Digital Angel Corp. (Nasdaq: DIGA).